Posts

Novartis AG said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of generic versions of its Exforge hypertension drug.

E-cigarette maker Juul Labs on Tuesday said it has reached settlements with about 10,000 plaintiffs covering more than 5,000 cases in California

Under the deals, first announced in July, Israel-based Teva will pay up to $4.25 billion, including a supply of the overdose drug naloxone. AbbVie will pay up to $2.37 billion. The final amounts of the settlements will depend on how many state and local governments opt into them.

Teva Pharmaceuticals will pay up to $4.2 billion in the United States to settle claims related to its role in fueling the country’s opioid crisis, New York Attorney General Letitia James said on Thursday.

CVS said it had agreed to pay about $5 billion over 10 years, and Walgreens said that it had agreed to pay about $5.7 billion over 15 years. Neither company admitted wrongdoing. Walmart has agreed to pay $3.1 billion, mostly up front, according to two people familiar with the matter.

The lawsuit accused Biogen of directing millions of dollars in kickbacks to doctors to prescribe its MS drugs Avonex, Tysabri and Tecfidera from 2009 to 2014, with kickbacks delivered in the form of “sham” consulting deals and speaker programs as well as lavish dinners and entertainment.

Johnson & Johnson (J&J) has reached a A$300 million ($204.90 million) settlement in two Australian class action suits filed by Shine Lawyers for selling defective pelvic mesh implants to Australian women, the law firm said on Monday.

West Virginia’s cities and counties reached a $400 million settlement on Monday with drug distributors McKesson Corp., AmerisourceBergen Corp., and Cardinal Health Inc., resolving the local governments’ allegations that the three companies fueled an opioid crisis in the state.

The company faces more than 3,000 lawsuits from state and local governments around the country over the drug. No final deal has been announced and AbbVie denies wrongdoing.

AbbVie Inc.’s unit Allergan has reached an agreement to pay over $2 billion to resolve thousands of lawsuits related to the marketing of its opioid painkiller, Bloomberg News reported on Wednesday, citing people familiar with the matter.